4.0 Article

Association of serum regenerating islet-derived protein 3-beta and oncostatin-M levels with the risk of acute coronary syndrome in patients with type 2 diabetes mellitus - A pilot study

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.dsx.2020.06.026

关键词

Type 2 diabetes mellitus; Acute coronary syndrome; Oncostatin-M; Regenerating islet-derived protein 3-beta

资金

  1. JIPMER Intramural Research Committee [JIP/Res/Intramural/phs2/2018-19]

向作者/读者索取更多资源

Background and aims: Regenerating islet-derived protein 3-beta (Reg3 beta) and oncostatin-M (OSM), an inducer of Reg3 beta, are important for the recruitment of macrophages, tissue repair and survival after myocardial infarction. The study was planned to elucidate the diagnostic utility of serum Reg3 beta and OSM levels for the acute coronary syndrome (ACS). Methods: Forty-two type 2 diabetes mellitus (T2DM) patients with ACS as cases and forty-two T2DM patients as controls were recruited. Routine biochemical investigations, creatine kinase-total (CK-T), and creatine kinase-MB (CK-MB) levels were estimated. Serum Reg3 beta and OSM levels were analysed by enzyme-linked immunosorbent assay. Results: Serum Reg3 beta and OSM levels were significantly higher in cases as compared to controls. Serum Reg3 beta and OSM levels were positively correlated with random blood glucose, serum CK-total, CK-MB levels, and negatively correlated with serum high-density lipoprotein cholesterol (HDL-C) levels. Receiver operating characteristics curve analysis showed that serum OSM and Reg3 beta levels can be used for the diagnosis of ACS in patients with T2DM as compared to CK-MB levels. On regression analysis, serum Reg3 beta level was positively associated with body mass index and negatively with serum HDL-C levels and serum OSM level was positively associated with waist circumference and random blood glucose and negatively with serum HDL-C levels. Conclusion: Serum Reg3 beta and OSM levels may be used as complementary markers besides traditional cardiac markers for the diagnosis of ACS in patients with T2DM. However, further studies are still needed to verify our claim. (c) 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据